- Info
- Significant Ownership
Significant Ownership of Sofinnova Venture Partners IX, L.P.
- Signature - Title
- /s/ Nathalie Auber - Nathalie Auber/Attorney-in-Fact
- Location
- Menlo Park, CA
- Summary
- This page shows a list of all the recent SCHEDULE 13D/G filings made by Sofinnova Venture Partners IX, L.P..
Follow Filing Activity
Follow Sofinnova Venture Partners IX, L.P. and return when a new Schedule 13D/G filing appears.
This tracks SEC filing changes for this page using existing product update flows.
Continue schedule research
Related filing hubs for this reporting manager, useful for reinforcing crawl paths across the schedule cluster.
Significant Ownership of Sofinnova Venture Partners IX, L.P.
| Sym | Company | Class | Ownership | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|---|
| NXTC | NextCure, Inc. | Common Stock, $0.001 par value | 7.1% | $2,947,939 | 222,654 | Sofinnova Venture Partners IX, L.P. ("SVP IX") | 19 Dec 2025 | ||
| AVBP | ArriVent Biopharma, Inc. | Common Stock, $0.0001 Par Value per Share | 4.1% | $35,767,532 | 1,696,752 | Sofinnova Venture Partners XI, L.P. ("SVP XI") | 31 Dec 2025 |
Schedules 13D/G Reported by Sofinnova Venture Partners IX, L.P.:
| Sym | Target | Class | Ownership | Change | Current Shares | Change | Value | Reporting name | Form | Report Period | Filing Date |
|---|
* An asterisk sign (*) next to the price indicates that the price is likely invalid.